Immunize.org supports evidence-based vaccination recommendations and schedules. Read more at About Us.

Ask the Experts: RSV (Respiratory Syncytial Virus): Scheduling & Documentation (Vaccines and Antibody)

Results (7)

Yes, influenza and RSV vaccines may be administered at the same visit. CDC has provided the details of available information in its guidance on RSV vaccination of older adults:  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html.

CDC advises that when deciding whether or not to coadminister other vaccines with an RSV vaccine, consider whether the patient is up to date with currently recommended vaccines, the feasibility of the patient returning for additional vaccine doses, their risk for acquiring vaccine-preventable disease, vaccine reactogenicity profiles, and patient preferences.

The National Adult and Influenza Immunization Summit (NAIIS) produced a data table summarizing the available data on coadministration of adult vaccines, including RSV and influenza. The reference is available here: www.izsummitpartners.org/wp-content/uploads/NAIIS-co-administration-of-vaccines.pdf.

Last reviewed: November 8, 2026

Both the American Academy of Family Physicians (AAFP) and CDC advise that vaccination will have the most benefit if administered in late summer or early fall, just before the RSV season. In most of the continental United States, this corresponds to vaccination during August–October.

If you have an opportunity to vaccinate an eligible patient and are concerned that there will not be an opportunity to vaccinate during an ideal time of year, you may administer RSV vaccine at any time of year. A meaningful degree of protection after vaccination should last at least two years.

Last reviewed: November 8, 2026

Both the American Academy of Pediatrics (AAP) and CDC recommend aiming for nirsevimab (Beyfortus, Sanofi) or clesrovimab (Enflonsia, Merck) administration in the first week of life for infants born shortly before or during the RSV season (typically October through March, unless directed otherwise by state or territorial public health officials). Ideally, eligible infants should be immunized before discharge from the birthing facility. Eligible infants with prolonged birth hospitalizations due to prematurity or other causes should be immunized shortly before or promptly after discharge.

Infants younger than age 8 months born outside of the RSV season, as well as older children at high risk who are recommended be protected in their second RSV season, should aim to be immunized shortly before the start of the RSV season (typically October).

If the ideal timing is missed, age-eligible infants and children who have not yet received a dose may be immunized at any time during the RSV season.

If you are located in Alaska, Hawaii, or another region of the United States with a different pattern of RSV circulation, follow the timing guidance of your state or territorial public health officials.

Last reviewed: November 8, 2026

CDC has published an “immunization information statement” (IIS) for RSV preventive antibody products that is the equivalent of the vaccine information statement (VIS) for vaccines. CDC directs providers to its RSV preventive antibody immunization information statement when administering either nirsevimab or clesrovimab. Use the current version rather than relying on an older saved copy. Just as with a VIS, CDC advises providers to give the immunization information statement to the parent or caregiver before immunization and document it in the medical record.

Access the current RSV preventive antibody IIS and translations in numerous languages from Immunize.org at: www.immunize.org/vaccines/vis/iis-rsv/.

The American Academy of Pediatrics (AAP) also offers immunization fact sheets for families in Spanish and English that can accompany an IIS or VIS. All are available here: www.aap.org/en/patient-care/immunizations/immunization-fact-sheets/.

Last reviewed: November 8, 2026

Yes. Administration of the RSV preventive antibody products (nirsevimab [Beyfortus, Sanofi] and clesrovimab [Enflonsia, Merck]) should be reported to your state immunization information system (IIS, or “registry”) as you would report vaccine administration. Contact your state immunization program if you have specific questions about reporting to your state immunization information system.

Last reviewed: November 8, 2026

It is important that prenatal and pediatric healthcare providers ensure that maternal RSV vaccination status is clearly documented and communicated. Prenatal care providers and birthing hospitals should ensure maternal RSV vaccination is reported to state immunization information systems (registries) and documented in maternal and newborn health records. It is also important to provide the pregnant person with a personal record of immunization.

Failure to document and communicate maternal RSV vaccination may result in extra work for pediatric offices and families to obtain records or in unnecessary administration of an RSV preventive antibody product.

The American College of Obstetricians and Gynecologists (ACOG) and CDC recommend maternal RSV vaccination only once at this time, so the history of RSV vaccination is also important information for future pregnancies when the mother would need to be counseled that RSV vaccination is not an option and the infant should receive a preventive antibody product after delivery for RSV prevention.

Last reviewed: November 8, 2026


1:48

View All Video Questions

Last reviewed: December 6, 2024

This page was updated on .